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OBJECTIVE— Both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
have been linked to systemic inflammation in nondiabetic cohorts. We examined the relation-
ships between VAT and SAT and systemic inflammatory markers in a large well-characterized
cohort of subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS— Three hundred eighty-two subjects with
type 2 diabetes in the CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using
Pioglitazone) study cohort underwent abdominal computed tomography to determine SAT and
VAT distribution. Fasting blood was obtained for measurement of inflammatory markers. The
relationships between inflammatory markers and BMI, SAT, and VAT were examined using
regression models adjusted for age, sex, diabetes treatment, duration of diabetes, smoking, statin
use, and A1C.
RESULTS— VAT was positively related to CRP, monocyte chemoattractant protein (MCP),
intracellular adhesion molecule (ICAM)-1, and plasminogen activator inhibitor type 1 (PAI-1)
antigen before adjustment for BMI. After adjustment for BMI, the relationship to CRP was lost but
positive associations with MCP (P  0.01), PAI-1 (P  0.0001), ICAM-1 (P  0.01), and
vascular cell adhesion molecule (P 0.01) were evident. BMI was positively related to CRP (P
0.0001) and IL-6 (P 0.01) even after adjustment for VAT and SAT. SAT was not related to any
inflammatory marker after adjustment for BMI.
CONCLUSIONS— In this large group of subjects with type 2 diabetes, BMI was most
strongly associated with CRP and IL-6 levels. SAT was not associated with markers of systemic
inflammation. The size of the VAT depot provided information additional to that provided by
BMI regarding inflammatory markers that are strongly related to vascular wall remodeling and
coagulation. Our findings suggest that adipose tissue distribution remains an important deter-
minant of systemic inflammation in type 2 diabetes.
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Obesity, especially of the abdominaltype, is associated with a proinflam-matory state. The association be-
tween obesity and inflammation was first
reported by Hotamisligil et al. (1), who
demonstrated expression of tumor necro-
sis factor- (TNF-) in adipose tissue, an
increase in its expression in obesity, and
its ability to induce insulin resistance.
Since this report, adipose tissue has been
recognized as an important source of a
number of hormones and cytokines, in-
cluding TNF-, interleukin (IL)-6, and
monocyte chemoattractant protein
(MCP)-1 (2). While adipokines such as
leptin and adiponectin are exclusively
produced by adipocytes, inflammatory
cytokines can be produced by both adi-
pocytes and adipose tissue macrophages
(ATMs) (2). Obesity is associated with an
increase in ATM infiltration (3) and acti-
vation (4). Epidemiological studies have
demonstrated an increase in plasma levels
of inflammatory markers such as C-reac-
tive protein (CRP), IL-6, and TNF- in
obesity and a strong association with
these levels and risk for type 2 diabetes
and cardiovascular disease (2,5). Weight
loss in humans has been associated with a
reduction in ATM infiltration and levels of
systemic inflammatory markers (6).
There is also evidence that adipose tissue
isolated from specific fat depots, such as
visceral fat, may express higher levels of
inflammatory markers such as IL-6 (7),
MCP-1 (8), and plasminogen activator in-
hibitor type 1 (PAI-1) (9).
For this report, we examined the as-
sociation between abdominal fat com-
partments measured by computed
tomography (CT) and markers of sys-
temic inflammation in 382 subjects with
type 2 diabetes who participated in the
Carotid Intima-Media Thickness in
Atherosclerosis Using Pioglitazone
(CHICAGO) study (10). To our knowl-
edge, this is the largest cohort in which
the relationship between adipose tissue
distribution (using abdominal CT) and
inflammation in subjects with type 2 dia-
betes has been examined. A recent study
of mostly non-Hispanic whites with low
prevalence of diabetes and cardiovascular
disease showed that both visceral adipose
tissue (VAT) and subcutaneous adipose
tissue (SAT) are associated with inflam-
matory markers, though the association
for VAT was stronger (11). In this analy-
sis, we determined whether adipose tissue
distribution and specific adipose tissue
depots remain important determinants of
systemic inflammation in type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Subjects for the current
analysis were Caucasian and African-
American participants in the CHICAGO
trial, a prospective study of the effects of
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pioglitazone compared with glimepiride
on carotid intima-media thickness in sub-
jects with type 2 diabetes (10). The details
of the study have been previously re-
ported (10). Data included in this report
were obtained before randomization to
treatment groups. The study was ap-
proved by central and local institutional
review board committees, and all partici-
pants provided written informed consent.
All subjects underwent measurements of
height, weight, and waist and hip circum-
ference by a trained nurse at the baseline
visit. Waist circumference was measured
at the smallest circumference between the
ribs and iliac crest, and hip circumference
was measured at maximum circumfer-
ence between the iliac crest and crotch to
the nearest 0.1 cm.
Subjects underwent an abdominal CT
scan for determination of VAT, SAT, and
total abdominal adipose tissue (TAT). Ab-
dominal adipose tissue content and dis-
tribution were quantified by CT scan at
the level of L4–L5 vertebrae while the
subjects were in supine position with
both arms stretched above the head. A
single 6-mm slice was taken during sus-
pended respiration after a normal expira-
tion. TAT was measured by delineating
the body surface with a receiver operator
instrument and then by computing the
adipose tissue volume using an attenua-
tion range of190 to30 HU. VAT area
was quantified by delineating the abdom-
inal cavity at the internal aspect of the
abdominal wall and the posterior aspect
of the vertebral body with the receiver op-
erator instrument. SAT area was calcu-
lated by subtracting VAT from TAT
volume. To obtain VAT, SAT, and TAT
volumes, the area for each fat component
was multiplied by the slice thickness.
Fasting blood samples were obtained at
the baseline visit for measurement of in-
flammatory markers and A1C. Inflamma-
tory markers were measured using kits
according to the manufacturer’s instruc-
tions: plasma CRP (Roche Diagnostics,
Indianapolis, IN), intracellular adhesion
molecule (ICAM)-1 and vascular cell ad-
hesion molecule (VCAM)-1 (R&D Sys-
tems, Minneapol i s , MN), matr ix
metalloproteinase (MMP)9 (R&D Sys-
tems), and PAI-1 (Trinity Biotech USA, St.
Louis, MO). Fibrinogen was measured by
direct coagulation analysis (Dade Behring
Marburg, Marburg, Germany), human in-
sulin by ELISA (Linco, St. Charles, MO),
and A1C by high-performance liquid
chromatography (Bio-Rad, Hercules,
CA). IL-6 was measured by ELISA (Quan-
tikine HS; R&D Systems).
Statistical methods
Log transformation of the data was per-
formed when it was necessary to achieve
homogeneity of variance. Sex differences in
inflammatory biomarkers, VAT, SAT, TAT,
and BMI were compared by ANCOVA ad-
justed for age, BMI, baseline diabetes treat-
ment, duration of diabetes, years of
smoking, statin use, and A1C.
Age- and sex-adjusted Pearson corre-
lation coefficients were used to assess the
relationship between BMI, waist circum-
ference, A1C, SAT, VAT, TAT, and each
inflammatory marker. We also performed
multivariable regression models adjusted
for age, sex, baseline diabetes treatment,
duration of diabetes, years of smoking,
statin use, and A1C to evaluate the rela-
tionship between each inflammatory
marker and SAT, VAT, and BMI. SAT,
VAT, and BMI were first standardized to
mean 0 and SD 1. We calculated regres-
sion coefficients quantifying the es-
timated change in log-transformed
biomarker per SD increase in SAT, VAT,
or BMI separately and then transformed
back to estimate the percent change in
each biomarker. The multivariable analy-
ses were repeated with addition of BMI to
the models when assessing the relation-
ship between VAT or SAT and inflamma-
tory markers or with the addition of both
VAT and SAT to the model when assess-
ing the relationship between BMI and in-
flammatory markers. The associations
between VAT and inflammatory markers
were further examined by multivariable
models after addition of SAT, or of hip
circumference, to models that included
BMI. Similar analyses were performed to
evaluate the associations between SAT
and inflammatory markers before and af-
ter adjustment for BMI or for BMI and
VAT. To further examine the role of
smoking, we repeated all of the above
analyses by placing smoking as a categor-
ical variable instead of years of smoking as
follows: current smokers (n  58), ex-
smokers (n 186), and nonsmokers (n
127). To evaluate whether the associa-
tions between abdominal fat depots and
inflammatory markers were related to the
degree of obesity, we repeated the above
analyses in two groups based on a median
split of BMI. Analyses were performed us-
ing the 11.0 PC package of SPSS statistical
software (SPSS, Chicago, IL). P  0.01
was considered significant in order to ad-
just for evaluation of multiple inflamma-
tory markers for their relationship to VAT
(which was our primary analysis).
RESULTS— The baseline characteris-
tics of study subjects are presented in Ta-
ble 1. The mean age was 61 years. Thirty-
eight percent of subjects were women,
55% were on statin therapy, and 65%
were current or former smokers. Subjects
were on the following diabetes therapy at
the time of participation in the study:
15% were not taking any medications for
diabetes, 15% were taking sulfonylureas,
29% were taking metformin, 31% were
taking a combination of metformin and
sulfonylureas, and 10% were on insulin
therapy. The average  SD BMI was
32.5  5.1 kg/m2, the mean duration of
type 2 diabetes was 92 86 months, and
the mean A1C was 7.4  0.9%. The me-
dian (interquartile range) CRP level was
2.7 mg/l (1.4 –5.5), ICAM-1 was 241
ng/ml (196 –294), MCP was 61 pg/ml
(43–61), VCAM-1 was 670 mg/dl (537–
816), fibrinogen was 322 mg/dl (249–
391), MMP9 was 439 ng/ml (305–613),
PAI-1 was 29 ng/ml (20–43), and IL-6
was 2.49 pg/ml (1.8 –3.8) (data not
shown).
Men had a higher amount of VAT
than women (P  0.0001), whereas
women had a higher amount of SAT than
men (P  0.0001) (Table 2). BMI and
Table 1—Baseline characteristics of study
participants
Age (years) 61  8
BMI (kg/m2) 32.5  5.1
Waist circumference (cm) 108  13
Hip circumference (cm) 113  12
Duration of type 2 diabetes
(months) 92  86
A1C (%) 7.4  0.9
Smoking
Current 16
Former 49
Never 35
Diabetes therapy
None 15
Sulfonylurea 15
Metformin 29
Sulfonylurea and metformin 31
Insulin 10
Statin use
Statin 55
No statin 45
Sex
Men 62
Women 38
Data are means  SD or %. Study participants are
subjects with type 2 diabetes (n  382).
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TAT were similar between men and
women. CRP and fibrinogen levels were
higher in women than men (P 0.0001)
(Table 2).
In age- and sex-adjusted correlations
(Table 3), VAT was positively associated
with CRP, ICAM-1, MCP, MMP9, and
PAI-1. BMI was positively associated with
CRP, fibrinogen, PAI-1, and IL-6,
whereas SAT was positively associated
only with CRP (Table 3). TAT was posi-
tively associated with CRP, ICAM-1, and
PAI-1. Waist circumference was posi-
tively associated with CRP, ICAM-1,
MMP9, PAI-1, and IL-6 (Table 3). A1C
was not associated with any of the inflam-
matory markers (Table 3).
The results from multivariable regres-
sion models adjusted for age, sex, diabe-
tes treatment, duration of diabetes, A1C,
and smoking years are shown in Table 4.
The percent change in each inflammatory
marker per SD of adiposity measurement
is given for significant associations. We
also adjusted for statin use, as these drugs
have been shown to influence the levels of
circulating inflammatory markers (12).
After these adjustments, VAT remained
positively associated with CRP, ICAM-1,
MCP, and PAI-1 (Table 4). After addition
of BMI to the model, the association of
VAT with CRP was no longer evident;
however, VAT remained associated with
ICAM-1, MCP, and PAI-1, and a positive
association was observed between VAT
and VCAM-1 (Table 4). BMI was strongly
and positively associated with CRP and
IL-6, and the associations persisted after
adjustment for VAT and SAT (Table 4).
The relationship between CRP and BMI
was stronger in women (R2  0.32; P 
0.001) than men (R2  0.17; P  0.02)
even after adjustment for VAT and SAT
(data not shown). BMI was also positively
associated with fibrinogen and MMP9;
however, the significant association was
lost after adjustment for VAT and SAT
(Table 4). SAT was associated with CRP
and IL-6 but not after adjustment for BMI
(Table 4). Adjustment for smoking as a
categorical variable rather than years of
smoking did not alter any of these associ-
ations. Tests for heterogeneity (Caucasian
vs. African American) were not signifi-
cant for any of the associations shown in
Table 4.
Even though SAT was not associated
with any of the inflammatory markers, we
tested whether it altered the association of
VAT with these markers. We added SAT
to the multivariable model analyzing the
relationship between VAT and the inflam-
matory markers, and this addition did not
modify the association between VAT and
any of the inflammatory markers (data
not shown). It has also been suggested
that lower-body SAT may mitigate the ad-
verse influence of VAT on cardiometa-
bolic risk. We therefore added hip
circumference, as an index of lower-body
subcutaneous fat mass, to the multivari-
able model for the relationship between
VAT and inflammatory markers. The ad-
dition of hip circumference to the multi-
variable model also did not significantly
alter the association between VAT and
any of the inflammatory markers (data
not shown).
As noted above, our results differ
from those reported in a large cohort of
predominantly nondiabetic and less
obese subjects (11). In order to gain in-
sight into whether this difference is re-
lated to the presence of diabetes or to
more pronounced obesity in our cohort,
the associations between adipose tissue
depots and inflammatory markers were
examined separately in two groups based
on a median split of BMI at 31.1 kg/m2.
No independent associations between
SAT and any of the inflammatory markers
were observed in either BMI category. The
positive relationships between VAT and
PAI-1, MCP, ICAM-1, and VCAM-1 were
present in both BMI groups and were
stronger in the lower median split of BMI
(data not shown).
CONCLUSIONS— We found that
adipose tissue distribution is an impor-
tant determinant of systemic inflamma-
tion in a large, multiethnic population of
well-characterized subjects with type 2
diabetes. To our knowledge, this is the
largest cohort of subjects with type 2 dia-
betes who have undergone determination
of abdominal fat distribution by imaging
for analysis of its relationship to systemic
inflammation. VAT was positively associ-
ated with a number of inflammatory
markers even after adjustment for BMI.
BMI, independent of VAT and SAT, was
the primary determinant of CRP and IL-6.
After adjustment for BMI, SAT was not
Table 2—Sex differences in inflammatory markers, BMI, VAT, SAT, and TAT in type 2
diabetes
Men Women P*
CRP (mg/l) 2.3 (1.3–4.3) 3.6 (1.6–9.7) 0.0001
ICAM-1 (ng/ml) 243 (202–294) 234 (179–301) 0.7
MCP (pg/ml) 62 (44–89) 60 (43–87) 0.8
VCAM-1 (mg/dl) 682 (545–834) 656 (525–807) 0.07
Fibrinogen (mg/dl) 306 (245–375) 357 (276–421) 0.0001
MMP9 (ng/ml) 451 (318–658) 392 (298–559) 0.4
PAI-1 (ng/ml) 28 (20–43) 30 (21–44) 0.1
IL-6 (pg/ml) 2.4 (1.8–3.6) 2.5 (1.8–4.1) 0.9
BMI (kg/m2) 31.8 (28.4–35.2) 32.7 (28.6–38.4) 0.2
VAT (cm3) 137 (105–180) 103 (80–131) 0.0001
SAT (cm3) 175 (128–220) 220 (165–276) 0.0001
TAT (cm3) 311 (245–395) 328 (249–397) 0.9
Data are medians (interquartile range 25th–75th percentiles). *ANCOVA for comparison between sexes
adjusted for age, BMI, diabetes therapy, duration of diabetes, years of smoking, statin use, and A1C.
Table 3—Age- and sex-adjusted Pearson correlation coefficients between log-transformed
inflammatory markers and BMI, waist circumference, TAT, VAT, SAT, and A1C
BMI Waist TAT VAT SAT A1C
CRP 0.34* 0.26* 0.28* 0.18* 0.17* 0.003
ICAM-1 0.12 0.16* 0.17† 0.21* 0.08 0.02
MCP 0.05 0.03 0.06 0.16* 0.01 0.003
VCAM-1 0.04 0.05 0.02 0.10 0.04 0.02
Fibrinogen 0.16* 0.13 0.12 0.07 0.08 0.04
MMP9 0.13 0.18* 0.13 0.17* 0.04 0.03
PAI-1 0.14† 0.18* 0.18† 0.29* 0.05 0.04
IL-6 0.21* 0.19* 0.12 0.07 0.04 0.07
*P  0.001; †P  0.01.
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associated with any inflammatory mark-
ers. Interestingly, adjusting for SAT (in-
dex of central SAT) or hip circumference
(index of peripheral SAT) did not reduce
the importance of VAT for predicting sys-
temic inflammatory markers. Our find-
ings suggest that both BMI and VAT are
correlates of systemic inflammation in
obese subjects with type 2 diabetes. Fur-
thermore, VAT provides information ad-
ditional to BMI for a number of systemic
inflammatory markers that are strongly
associated with vascular remodeling and
coagulation (13–18).
An increase in inflammatory markers
has been associated with increased risk
for metabolic abnormalities and cardio-
vascular disease (2,5,19). Expansion of
adipose tissue explains these associations,
as it promotes a systemic inflammatory
response. Inflammatory molecules such
as TNF-, IL-6, serum amyloid A, and
MCP-1 are produced in significant quan-
tity by ATMs and adipocytes (2,5,19). Re-
cently, it has been shown that obesity is
associated with increased ATM infiltra-
tion (up to 40%) and a change in ATM
polarization to a more proinflammatory
state (3,4). Both SAT and VAT are known
to secrete inflammatory cytokines in vitro
and have been implicated in metabolic
disorders (7–9). Subcutaneous abdomi-
nal fat is divided into superficial and deep
layers by a fascial plane, and recent evi-
dence suggests that there maybe meta-
bolic differences between the two
components (20). For example, deep but
not superficial subcutaneous abdominal
tissue has been associated with peripheral
insulin resistance and features of meta-
bolic syndrome (20). We were not able to
separate these compartments in the cur-
rent study.
A recent study from the Framingham
cohort has shown that both VAT and SAT
are associated with CRP and a number of
other inflammatory markers, indepen-
dent of BMI; however, the associations
were stronger for VAT (11). Subjects in
the CHICAGO cohort were more obese
compared with the Framingham cohort,
and all had type 2 diabetes, whereas the
prevalence of type 2 diabetes in the Fra-
mingham cohort was 10% (11). There-
fore, while our data affirm the importance
of adipose tissue distribution on inflam-
matory markers in obese subjects even af-
Table 4—Multivariable-adjusted linear regression models for relation of SAT, VAT, or BMI to inflammatory markers
Multivariable model*
Multivariable model with SAT or VAT adjusted for
BMI or with BMI adjusted for both SAT and VAT
R2 P
Log difference  SE
per SD (% change†) R2 P
Log difference  SE per
SD (% change†)
CRP (mg/l)
SAT 0.23 0.0001 0.148  0.026 (41†) 0.26 0.07 0.063  0.034
VAT 0.16 0.003 0.088  0.029 (22†) 0.24 0.9 0.003  0.031
BMI 0.24 0.0001 0.159  0.023 (44†) 0.26 0.001 0.132  0.039 (36†)
ICAM-1 (ng/ml)
SAT 0.09 0.05 0.025  0.013 0.09 0.7 0.007  0.017
VAT 0.09 0.001 0.046  0.013 (11†) 0.09 0.008 0.040  0.015 (10†)
BMI 0.06 0.03 0.025  0.011 0.10 0.5 0.014  0.019
MCP (pg/ml)
SAT 0.10 0.9 0.001  0.016 0.10 0.7 0.008  0.022
VAT 0.13 0.001 0.057  0.017 (14†) 0.11 0.001 0.061  0.019 (15†)
BMI 0.09 0.2 0.017  0.014 0.12 0.6 0.013  0.024
VCAM-1 (mg/ml)
SAT 0.07 0.5 0.007  0.01 0.07 0.8 0.003  0.013
VAT 0.07 0.3 0.010  0.011 0.09 0.01 0.027  0.011 (6†)
BMI 0.07 0.3 0.009  0.009 0.09 0.1 0.021  0.015
Fibrinogen (mg/dl)
SAT 0.14 0.02 0.018  0.008 0.15 0.5 0.008  0.011
VAT 0.12 0.2 0.011  0.009 0.13 0.8 0.001  0.01
BMI 0.13 0.003 0.022  0.007 (5†) 0.15 0.2 0.017  0.012
MMP9 (ng/ml)
SAT 0.14 0.1 0.021  0.013 0.15 0.9 0.002  0.018
VAT 0.14 0.03 0.033  0.015 0.15 0.2 0.020  0.017
BMI 0.14 0.01 0.031  0.012 (7†) 0.17 0.2 0.027  0.020
PAI-1 (ng/ml)
SAT 0.12 0.3 0.015  0.016 0.14 0.4 0.019  0.021
VAT 0.18 0.0001 0.074  0.017 (19†) 0.17 0.0001 0.055  0.017 (14†)
BMI 0.13 0.02 0.033  0.014 0.17 0.3 0.023  0.024
IL-6 (pg/ml)
SAT 0.16 0.001 0.058  0.017 (14†) 0.17 0.3 0.021  0.022
VAT 0.10 0.07 0.025  0.016 0.14 0.8 0.006  0.02
BMI 0.15 0.0001 0.069  0.015 (17†) 0.17 0.01 0.062  0.025 (15†)
*Multivariable model is adjusted for age, sex, diabetes therapy, duration of diabetes, years of smoking, statin use, and A1C. †Percent change in inflammatory markers
for every 1-SD increase in VAT, SAT, or BMI.
Sam and Associates
DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009 935
ter the onset of diabetes, they also suggest
that relationships between specific adi-
pose tissue depots and inflammatory
markers may be modified by the onset of
diabetes. Similar to previous studies, we
observed sex differences in CRP and fi-
brinogen levels with higher levels in
women (21). We also found a stronger
association between CRP and BMI, inde-
pendent of VAT and SAT, in women.
In multivariable fully adjusted mod-
els, an increase in VAT was strongly asso-
ciated with an increase in PAI-1 levels
independent of BMI. A higher PAI-1
plasma level has been linked to a higher
risk of coronary heart disease in subjects
with type 2 diabetes (15). Both animal
and human studies suggest that PAI-1 ex-
pression is higher in VAT than SAT
(9,22). Our data support the strong asso-
ciation between VAT and PAI-1 levels, in-
dependent of BMI, in type 2 diabetes.
MCP-1 is a potent chemotactic factor for
monocytes (23) and has been associated
with cardiovascular disease and diabetes
(16). In the Framingham cohort, MCP-1
was more strongly associated with VAT
than with SAT (11). Our findings are sim-
ilar to the Framingham cohort, as we also
observed a strong correlation between
VAT and MCP-1 that was independent of
BMI. ICAM-1 and VCAM-1 are members
of the cellular adhesion molecule family
that have been implicated in inflamma-
tory and atherosclerotic processes (13).
Elevated levels of both have been reported
in obesity (24). In the Framingham co-
hort, both SAT and VAT were associated
with ICAM-1 but neither of these rela-
tions persisted after adjustment for BMI
(11). In contrast, in our study, VAT was
associated with ICAM-1 before and after
adjustment for BMI. In contrast to find-
ings in predominantly nondiabetic popu-
lations, we found no independent
relationships among BMI, VAT or SAT,
and fibrinogen or MMP9 in fully adjusted
models (11,25).
Although prospective studies will be
necessary to determine the causal nature
of these associations, our results suggest
that in obese subjects with type 2 diabe-
tes, both BMI and VAT are important
drivers of systemic inflammation. While
BMI is strongly associated with CRP and
IL-6 levels, VAT is the primary determi-
nant of ICAM, VCAM, MCP-1, and PAI-1.
ICAM and VCAM are found in the vessel
wall where their level of expression is re-
lated to atherosclerotic plaque remodel-
ing (13,17,18). MCP-1 and PAI-1 are
significant markers of cardiovascular dis-
ease risk (14–16). Our findings indicate
that adipose tissue distribution remains
an important determinant of systemic in-
flammation in type 2 diabetes. They un-
derscore the importance of managing
excess adiposity, including that in the vis-
ceral fat depot, for optimally managing
cardiovascular risk in subjects with type 2
diabetes.
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